Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium by Tarulli, Gerard A. et al.
RESEARCH ARTICLE Open Access
Hormone-sensing cells require Wip1 for paracrine
stimulation in normal and premalignant
mammary epithelium
Gerard A Tarulli1, Duvini De Silva2, Victor Ho1, Kamini Kunasegaran1, Kakaly Ghosh1, Bryan C Tan1,
Dmitry V Bulavin3 and Alexandra M Pietersen1,2,4*
Abstract
Introduction: The molecular circuitry of different cell types dictates their normal function as well as their response
to oncogene activation. For instance, mice lacking the Wip1 phosphatase (also known as PPM1D; protein
phosphatase magnesium-dependent 1D) have a delay in HER2/neu (human epidermal growth factor 2), but not
Wnt1-induced mammary tumor formation. This suggests a cell type-specific reliance on Wip1 for tumorigenesis,
because alveolar progenitor cells are the likely target for transformation in the MMTV(mouse mammary tumor
virus)-neu but not MMTV-wnt1 breast cancer model.
Methods: In this study, we used the Wip1-knockout mouse to identify the cell types that are dependent on Wip1
expression and therefore may be involved in the early stages of HER2/neu-induced tumorigenesis.
Results: We found that alveolar development during pregnancy was reduced in Wip1-knockout mice; however, this
was not attributable to changes in alveolar cells themselves. Unexpectedly, Wip1 allows steroid hormone-receptor-
positive cells but not alveolar progenitors to activate STAT5 (signal transducer and activator of transcription 5) in the
virgin state. In the absence of Wip1, hormone-receptor-positive cells have significantly reduced transcription of
RANKL (receptor activator of nuclear factor kappa-B ligand) and IGF2 (insulin-like growth factor 2), paracrine
stimulators of alveolar development. In the MMTV-neu model, HER2/neu activates STAT5 in alveolar progenitor cells
independent of Wip1, but HER2/neu does not override the defect in STAT5 activation in Wip1-deficient hormone-
sensing cells, and paracrine stimulation remains attenuated. Moreover, ERK (extracellular signal-regulated kinase)
activation by HER2/neu in hormone-sensing cells is also Wip1 dependent.
Conclusions: We identified Wip1 as a potentiator of prolactin and HER2/neu signaling strictly in the molecular
context of hormone-sensing cells. Furthermore, our findings highlight that hormone-sensing cells convert not only
estrogen and progesterone but also prolactin signals into paracrine instructions for mammary gland development.
The instructive role of hormone-sensing cells in premalignant development suggests targeting Wip1 or prolactin
signaling as an orthogonal strategy for inhibiting breast cancer development or relapse.
Introduction
Breast cancer consists of multiple subtypes, and it has
been postulated that the difference between subtypes
arises in part from the type of mammary epithelial cell
that transforms [1,2]. The molecular circuitry of a particu-
lar cell type determines how it responds to activation of a
signaling pathway and likely dictates the sensitivity of that
cell to particular oncogenic mutations [3]. For instance,
Wip1-knockout mice have a delay in tumorigenesis in the
MMTV-neu model of breast cancer, but not in the
MMTV-wnt1 model [4]. Wip1 is overexpressed in ~20%
of human breast cancer cases, which belong mostly to the
luminal and HER2+ subtypes [5]. Together, this suggests
that the target cells for transformation by HER2/neu
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activation are dependent on Wip1, whereas those that can
be transformed by Wnt1 are not.
Wip1 is a serine/threonine phosphatase of the PP2C
(protein phosphatase 2C) family, and its oncogenic func-
tion has been attributed to, for instance, its role as a nega-
tive regulator of p53 by dephosphorylating key members
of DNA-damage signaling, including ATM, Chk2, and p53
itself [6]. In addition, Wip1 dephosphorylates and thereby
inactivates the stress kinase p38MAPK, and inhibition of
p38MAPK in Wip1-knockout mice partially restored sen-
sitivity to MMTV-neu-induced tumorigenesis [7]. In this
study, we examined the role of Wip1 in mammary epithe-
lium to identify the cell types that are dependent on Wip1
activity and therefore may be involved in the early stages
of HER2/neu-induced tumorigenesis.
Mammary epithelium consists of an outer basal layer of
mainly contractile myoepithelial cells and an inner luminal
layer that contains both steroid-receptor-positive cells and
steroid-receptor-negative cells in a spatially ordered pat-
tern [8]. Mammary gland development during puberty is
orchestrated by the steroid sex hormones estrogen and
progesterone, which trigger proliferation indirectly in ster-
oid-receptor-negative cells through paracrine factors pro-
duced by steroid-receptor-positive cells. Interestingly,
steroid-receptor-positive cells act mainly as a conduit for
proliferative signals, as they rarely divide themselves [9,10].
The luminal steroid-receptor-negative cells contain differ-
ent progenitor subsets, including alveolar progenitor cells
that are primed for milk production [11-13]. During the
initial phase of pregnancy, progesterone, together with the
peptide-hormone prolactin, triggers a massive expansion
of the alveolar cell population in a process termed lobulo-
alveologenesis, followed by terminal differentiation of the
alveolar cells later in pregnancy [14,15]. Both processes are
strictly dependent on prolactin signaling, as any mutant in
the prolactin receptor-JAK2-STAT5 signaling cascade has
a defect in alveolar development [16-18], and even after
alveologenesis has been completed, lactation remains
dependent on STAT5 expression [19]. Activation of the
prolactin receptor results in activation of the associated
JAK2, which subsequently phosphorylates STAT5, allow-
ing STAT5 to translocate to the nucleus and activate gene
transcription [20]. STAT5 directly binds to the promoter
of milk genes, suggesting that in mammary epithelium,
alveolar cells are the principal responders to prolactin [21].
The cells most likely to be sensitive to transformation by
Wnt1 are stem or progenitor cells that are part of the
basal layer [22,23]. In contrast, compelling evidence sug-
gests that the target cell for transformation in the MMTV-
neu model belongs to the alveolar lineage. Whey acidic
protein (WAP) is one of the components of milk that is
expressed late during alveolar differentiation. Lineage tra-
cing with a WAP-promoter-driven Cre recombinase,
together with a Rosa-lox-stop-lox-LacZ reporter, showed
that early lesions in MMTV-neu mammary glands are all
LacZ-positive, indicating that these cells expressed milk
genes at some point [24]. These LacZ-marked cells are
also referred to as parity-identified mammary epithelial
cells (PI-MECs) or lobule-restricted progenitors [25].
Strikingly, mice with a cyclin D1 point mutation generate
normal mammary ducts, but no PI-MECs, and are com-
pletely resistant to MMTV-neu tumorigenesis [26].
In line with the presumptive alveolar origin of HER2/
neu-driven tumors and the attenuation of tumorigenesis in
the absence of Wip1, we found delayed alveolar develop-
ment during pregnancy in Wip1-knockout mammary
glands. Unexpectedly, we identify a role for Wip1 in
steroid-receptor-positive cells rather than adjacent alveolar
progenitor cells. We show that in the virgin state, only
steroid-receptor-positive cells activate STAT5, and this is
strictly dependent on Wip1. Unlike alveolar cells that tran-
scribe milk genes after STAT5 activation, hormone-sensing
cells transcribe paracrine stimulators of alveolar prolifera-
tion (RANKL and IGF2), elucidating a role for steroid-
receptor-positive cells in the growth-promoting rather than
differentiation-inducing effects of prolactin. MMTV-neu
tumors are estrogen-receptor negative but we show that
before tumor formation, ERK activation by HER2/neu is
most pronounced in steroid-receptor-positive cells, and
this is dependent on Wip1. Finally, in virginWip1-knockout
mice, HER2/neu activates STAT5 in alveolar progenitors
but not steroid-receptor-positive cells, and paracrine sig-
naling remains attenuated. This suggests that the target
cells for transformation in the MMTV-neu model rely on
Wip1-dependent signaling in neighboring cells, highlight-
ing the instructive role of hormone-sensing cells in early
pregnancy and premalignant development.
Materials and methods
Mice
Wip1 KO (Ppm1d-/-) mice were previously described [27]
(129Sv-C57BL/6-FVB background). We observed no dif-
ference between Wip1 wild-type or heterozygote animals
in the context of alveolar development, STAT5 activation
or qPCR data, and therefore the “wild-type” control
groups presented here consist of a mixture of wild-type
and heterozygote animals. MMTV-neu mice used for this
study (and [4,26]) express the activated rat ErbB2 (c-neu)
oncogene under control of the mouse mammary tumor
virus promoter (strain TG.NK) [28] and were purchased
from the Jackson Laboratory (Jax#5038, FVB back-
ground). All animal protocols were approved by the
SingHealth Institute Animal Care and Use Committee.
Timed mating and carmine staining of whole-mounted
mammary glands
Female mice were placed in the cage of a male after 5 PM
and checked for vaginal plugs at 9 AM the following
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morning (Day 0). Mice were killed by carbon dioxide
inhalation and one number 3 (thoracic) gland was fixed in
methacarn (60% methanol, 30% chloroform, 10% acetic
acid) for 24 hours. Subsequently, the gland was placed in
70% ethanol for 24 hours, and then immersed in 0.2%
carmine (Sigma C1022, St. Louis, MO, USA)/0.5% alumi-
num potassium sulfate (Sigma-Aldrich #23,708-6,
St. Louis, MO, USA) stain for 18 hours. Next, glands were
transferred to 70%, 90%, and 100% ethanol for 1 hour
each, followed by 100% ethanol for 18 hours. Finally,
glands were transferred to methyl salicylate (Sigma
M2047, St. Louis, MO, USA) for visualization and photo-
graphy with an Olympus SZX12 microscope.
Isolation of primary mammary epithelial cells
Mammary epithelial cells were isolated [29], with minor
modifications. Mice were killed by carbon dioxide inhala-
tion and the number 4 (inguinal) and 5 mammary glands
were excised after removal of mammary lymph nodes.
Glands were chopped 3 times by using a McIlwain tissue
chopper (Mickle Laboratory Engineering, Guildford, UK)
on the finest setting, with a 90-degree rotation of the
base plate between each round of chopping. Chopped
glands from one animal were then placed in 10 ml diges-
tion mix containing 3 mg/ml of collagenase A (Roche
11088793001, Mannheim, Germany) and 0.67 mg/ml
trypsin (Becton Dickinson (BD) 215240, Sparks, MD, USA)
at 37°C for 45 minutes with agitation every 15 minutes.
Digested glands were subsequently centrifuged at 1,300
rpm (340 rcf) for 6 minutes at 4°C, and the fat layer and
supernatant removed. The pellet (containing mammary
epithelial organoids) was resuspended in 10 ml of L15
media (Sigma L1518, St. Louis, MO, USA) containing 6%
fetal calf serum (Hyclone SV30160.03, Cramlington, UK)
and centrifuged at 1,500 rpm (453 rcf) at room tempera-
ture. Supernatant was removed, and the pellet was resus-
pended in 5 ml of red blood cell lysis buffer (Sigma R7757,
St. Louis, MO, USA) and incubated at room temperature
for 5 minutes before centrifugation at 1,500 rpm for 5
minutes at 4°C. From this point, all centrifugation steps
were performed at 1,500 rpm at 4°C. Pellet was then resus-
pended in DMEM +10% FCS and incubated for 30 minutes
at 37°C in a T75 flask to allow the selective adherence of
fibroblasts. Media containing organoids were collected and
centrifuged. Supernatant was removed, and organoids were
resuspended in L15 + 6% FCS (L15+) and kept overnight
at 4°C. The next day, organoids were pelleted, washed
twice in Ca2+/Mg2+-free PBS/0.02% wt/vol EDTA and
incubated in 2 ml of Joklik MEM (Sigma M8028, St. Louis,
MO, USA) for 15 minutes at 37°C. Organoids were centri-
fuged and resuspended in 2 ml of 0.25% trypsin-0.04%
EDTA solution (Gibco 25200, Grand Island, NY, USA) and
placed at 37°C for 2 minutes to generate single cells. Next,
5 ml of 5 μg/ml DNase I (type II) in serum-free L15
(Sigma D4527, St. Louis, MO, USA) was added for a
further 5 minutes at 37°C to disperse cellular clumps.
Then, 7 ml of L15+ was added (henceforth, all resuspen-
sions were performed by using L15+), and the cell solution
was passed through a 40-μm cell strainer (BD 352340,
Sparks, MD, USA). The resultant single cells were pelleted,
resuspended in L15+, and counted by using trypan blue
and a hemocytometer. Cells were brought to a concentra-
tion of 1 × 106/ml and kept on ice.
Cell labeling, flow-cytometric analysis, and fluorescence-
activated cell sorting
Fluorochrome-conjugated antibodies were titrated on
primary mammary epithelial cells to ensure maximal
positive-to-background fluorescence ratio (see Additional
file 1). Anti-mouse and/or anti-rat compensation beads
(BD 552843 and 552845, respectively) were used for
single-stain antibody controls. Compensation controls
also included two cellular samples: unstained cells and
cells with DAPI (Sigma D8417, St. Louis, MO, USA).
Cells were incubated with antibodies on ice for 45 min-
utes with agitation each 15 minutes. Samples were then
washed with twice the sample volume and resuspended
in L15+ containing 200 ng/ml of DAPI, except non-
DAPI compensation controls. All multiple-labeled
samples were gated on FSC-A versus SSC-A and doublet
discrimination (FSC-H versus FSC-W and SSC-H versus
SSC-W) and DAPI negativity (see Additional file 2).
Samples contained anti-CD45 to exclude lymphocytes
from analysis. Cells were analyzed and sorted on a BD
FACS-Aria II containing 355 nm UV, 488 nm blue, 561
nm yellow-green, and 633 nm red lasers. Sorting for
culture or in vivo assays was performed into L15+.
Generation of cDNA by direct reverse transcription and
qPCR analysis
For analysis of transcript levels by quantitative polymerase
chain reaction (qPCR), cells were sorted directly into lysis
buffer (10 IU RNase inhibitor (Invitrogen 10777, Carlsbad,
CA, USA), 2 mM DTT, 0.15% Tween-20 (Biorad) in 12 μl
of nuclease-free water) in PCR tubes. Then 500 cells were
sorted into each tube (making approximately 14 μl total
volume). Reverse transcription was performed by using
Superscript VILO (Invitrogen 11754, Carlsbad, CA, USA),
as per manufacturer’s protocol. Primers were designed
that span introns to exclude the detection of genomic
DNA and selected for optimal melt curve and amplifica-
tion profiles (for primer sequences (see Additional file 3).
qPCR was performed by using SSo Fast Evagreen super-
mix reagent (Biorad 172-500, Hercules, CA, USA) as per
manufacturer’s protocol. Per subpopulation, two to three
tubes were assayed, normalized with HPRT (validated to
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be consistent between groups), averaged, and compared
with matched WT samples according to the delta-delta
c(t) method. The relative values from three to five sets
of mice were assessed with paired t test for statistical
significance.
Mammary gland transplantation and immunofluorescence
The number 4 and 5 mammary glands were harvested
from donor mice, and the mammary glands digested and
sorted, as outlined earlier. Then 25,000 bulk epithelial cells
were injected into cleared number 4 fat pads of 21-day-old
WT-recipient mice and allowed to engraft for 8 weeks.
Glands were then harvested, fixed, and stained with
carmine alum, as outlined earlier. After whole-mount
analysis, glands were removed from methyl salicylate and
washed 5 times for 1 hour in 100% EtOH before immer-
sion in xylene for 2 × 1 hour. Tissue was then embedded
in paraffin and processed for immunofluorescence.
Confocal immunofluorescence
Fresh number 3 mammary glands were fixed for 18
hours in 4% buffered formaldehyde (ICM Pharma, Sin-
gapore), processed, and embedded in paraffin wax. The
5-μm sections were cut and adhered to Superfrost Plus-
coated slides (Menzel-Glaser J1800AMNZ, Braunsch-
weig, Germany) overnight at 37°C. Sections were depar-
affinized in xylene (2 × 5 minutes) and 100% ethanol
(2 × 5 minutes), before rehydration in graded ethanol
(90%, 2 × 5 minutes; 70%, 2 × 5 minutes) and immer-
sion in distilled H2O. Antigen retrieval was performed
in 600 ml of 1 mM disodium-EDTA by heating in a
microwave on high for 5 minutes, on 30% power for an
additional 5 minutes, and then cooled at room tempera-
ture for 1 hour. Slides were immersed in distilled H2O
and washed in PBS for 5 minutes. Sections were
encircled with a wax pen and primary antibody diluted in
PBS (for dilutions and suppliers, see Additional file 1) +
10% normal serum from the species in which the second-
ary antibody was raised, was applied and incubated at
4°C overnight. Sections were washed in PBS (2 × 5 min-
utes) before the addition of secondary antibody (in PBS
+ 10% normal serum), for 30 minutes at room tempera-
ture. Sections were washed in PBS (2 × 5 minutes)
before the addition of DAPI (1 μg/ml) for 2 minutes at
room temperature. Sections were then washed in PBS
and mounted in Vectashield fluorescence mounting
media (Vector Laboratories H-1000, Burlingame, CA,
USA) for visualization. Images were acquired on a Zeiss
710 confocal microscope with a pinhole aperture of 1
Airy unit. Negative controls can be found in Additional
file 4. For cell enumeration, at least seven fields were
randomly selected, and > 1,000 cells were counted per
animal.
Results
Wip1-knockout animals have reduced alveolar
development during pregnancy
To elucidate the role of Wip1 in mammary epithelium, we
assessed mammary gland development in Wip1-deficient
mice at adulthood and during pregnancy. We first exam-
ined the morphology of the ductal system by carmine
staining of whole mammary glands (Figure 1A, B). The
mammary ducts of adult virgin females were indistinguish-
able between wild-type (WT) and Wip1-knockout (Wip1
KO) mice. Because the mammary gland responds to fluc-
tuations in hormone levels across the estrus cycle by gen-
erating and regressing side branches and alveoli on a small
scale, we compared each Wip1 KO gland with a control
gland from a WT mouse in the same estrus stage (metoes-
trus). Examination of the ductal architecture at the cellular
level with hematoxylin and eosin (H&E) staining of tissue
sections (Figure 1C, D) revealed morphologically normal
bilayered ducts with proper lumens in the Wip1 KO. To
evaluate the effect of loss of Wip1 on alveolar develop-
ment during pregnancy, animals were timed-mated, and
glands were collected at 3, 7, and 14 days of pregnancy. In
WT mammary glands, the formation of alveoli becomes
evident with carmine whole-mount staining at 7 days of
pregnancy, with a further increase in number and size of
the alveolar lobules by day 14 of pregnancy (Figure 1A). In
contrast, generation of alveolar lobules in Wip1 KO glands
is substantially delayed. Analyses of tissue sections show
that the initiation of mammary alveolar development can
already be detected with H&E in 3-day pregnant WT
mice, whereas this is observed only in 7-day pregnant
Wip1 KO animals (Figure 1C, D). In WT mammary
glands at 14 days of pregnancy, distended lumens become
apparent in the developing alveoli, but in the absence of
Wip1, the alveolar architecture still resembles that of the
WT at 7 days of pregnancy (Figure 1C, D). It is note-
worthy that Wip1 KO animals are eventually able to nurse
their pups, indicating that alveolar development progresses
all the way to functional lactation, but our analyses show
an obvious delay in alveologenesis during the initial phase
of pregnancy.
Wip1 is required for STAT5 activation in a subset of
luminal cells
To determine the molecular cause of reduced alveolar
development in Wip1-deficient mammary glands, we
assessed the activation status of STAT5, an essential reg-
ulator of alveolar development [30]. Dual confocal immu-
nofluorescence of phosphorylated STAT5 (the active
form) and cytokeratin-8 (a marker for cells in the luminal
layer) was performed on sections of fixed tissue. We first
examined mammary glands from virgin animals and
found strong P-STAT5 staining in a subset of luminal
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cells in wild-type tissue (Figure 2A, red). In contrast,
P-STAT5 was very low in the absence of Wip1 (Figure 2B,
with quantification in 2E). This is due to a lack of phos-
phorylation, because STAT5 protein expression is com-
parable between Wip1 KO and WT mammary epithelium
(Figure 2C, D, red). In rare cells, weak P-STAT5 staining
was detectable in Wip1 KO tissue (white arrow in Figure
2B), indicating that STAT5 activation was severely attenu-
ated but not entirely abrogated. Although fluctuations in
P-STAT5 were observed in WT mice across the estrus
cycle, as previously reported [31], the signal for P-STAT5
remained lower in Wip1 KO mice compared with WT
mice, independent of estrus stage (data not shown).
To exclude the possibility that the lack of STAT5 activa-
tion in Wip1 KO mammary epithelial cells was due a sys-
temic defect, such as a requirement for Wip1 in prolactin
production from the pituitary gland, primary mammary















Figure 1 Wip1-knockout animals have reduced alveolar development during pregnancy. (A, B) Carmine-alum-stained whole mounts of
mammary glands from virgin (nulliparous) or 3-days (3d), 7-days (7d), or 14-days (14d) pregnant wild-type (WT, blue box) or Wip1-knockout (KO,
green box) mice. Images are representative of three to five animals. Scale bar, 500 μm. (C, D) Hematoxylin and eosin-stained tissue sections of
mammary glands from WT (blue box) or Wip1 KO (green box) virgin and pregnant mice, as indicated earlier. Black arrows, distention of lumens
present in WT alveolar lobules at 14 days of pregnancy, which are reduced in Wip1 KO sections. Insets are enlarged regions to visualize bilayered
epithelium. Dotted lines, location of basement membrane. Images are representative of three animals/group. Scale bar, 100 μm.
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into mammary fat pads of WT mice, from which the
endogenous mammary epithelium had been removed. We
found no difference in the capacity of WT or Wip1 KO
cells to reconstitute a mammary epithelial ductal system
in the cleared fat pads (data not shown). However,
whereas reconstituted mammary epithelium from WT
donors exhibited robust P-STAT5 immunoreactivity
(Figure 2F, red), Wip1 KO mammary epithelial cells in the
contralateral fat pad of the same animal failed to activate



















































Figure 2 Wip1 is required for STAT5 activation in a subset of luminal cells. (A, B) Confocal immunofluorescence of mammary gland
sections from virgin wild-type (WT, A) and Wip1-knockout (KO, B) mice, detecting phosphorylated signal transducer and activator of transcription
5 (P-STAT5, red) and the luminal cell marker cytokeratin-8 (CK8, green). Middle panels, enlarged sections of images shown in A and B. White
arrows, representative luminal cells with the strongest P-STAT5-positive signal for that genotype. Red signal outside context of CK8 is nonspecific
staining of erythrocytes. Control staining without primary antibody can be found in Additional file 4. (C, D) Same set of tissue samples probed
with antibodies against STAT5 (Total-STAT5, red) and cytokeratin-8 (CK8, green). (E) Quantification of the percentage of phospho-STAT5-positive
cells in WT (blue bar) and Wip1 KO mice (green bar). Values are presented as the mean proportions from five mice/group ± SD. ***P < 0.001.
(F, G) Outgrowths from WT and Wip1 KO mammary epithelial cells 8 weeks after transplantation into WT cleared mammary fat pads and probed
for P-STAT5 (red) and cytokeratin-8 (green). DAPI counterstain indicates cell nuclei (gray). Scale bar, 10 μm.
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cell-autonomous requirement exists for Wip1 expression
to activate STAT5 in mammary epithelial cells.
Steroid-receptor-positive cells require Wip1 to respond to
low levels of prolactin
In wild-type mammary ducts, activated STAT5 was
observed in only a subset of luminal cells. To determine
whether these are alveolar cells or steroid-receptor-posi-
tive cells, co-localization of P-STAT5 with estrogen
receptor-a (ER) was determined with confocal micro-
scopy. Surprisingly, virtually all P-STAT5-positive cells
were also positive for ER (Figure 3A) or the progester-
one receptor (PR; see Additional file 5A), demonstrating
that steroid-receptor-positive cells are the principal cells
to activate STAT5 in the virgin state. Notably, Nevalai-
nen et al. [32] showed that in virgin mammary epithe-
lium, the activation of STAT5 occurs exclusively
through the prolactin receptor. Steroid-receptor-positive
cells have been designated “sensor cells” based on their
response to estrogen and progesterone [8], but their
sensitivity to prolactin further emphasizes their role as
primary sensors for systemic cues, and we henceforth
refer to them as hormone-sensing cells. Hormone-sen-
sing cells stain more intensely with the cytokeratin-8
antibody (Figure 3A), and have a more cuboidal appear-
ance compared with columnar alveolar progenitor cells
[12]. The alveolar identity of the ER-negative, columnar
cells is demonstrated by their expression of Elf5 ([12],
Additional file 5B), and even though likely other pro-
genitor cells occur among the ER-negative cells, for
clarity purposes, ER-negative luminal cells are hence-
forth referred to as alveolar progenitor cells.
Thus, in WT mammary epithelium, phosphorylation
of STAT5 is restricted to ER-positive cells, even though
STAT5 protein is detectable in both alveolar progenitor-
and hormone-sensing cells (Additional file 5C). In the
absence of Wip1, STAT5 protein is still present in both
cell populations (Additional file 5D), but a conspicuous
absence of phosphorylated STAT5 is observed in the
ER-positive cells (Figure 3B). Together, these findings
raise the possibility that the hormone-sensing cells,
rather than the alveolar progenitor cells, are directly
affected by loss of Wip1. Accordingly, we found a small
but significant reduction in the number of ER-positive
cells in Wip1-deficient mammary glands (Figure 3C). In
summary, these experiments indicate that Wip1 is
required for hormone-sensing cells to respond to the
low levels of prolactin in the virgin state. During preg-
nancy, prolactin levels increase 10- to 20-fold [33], and
in sections from timed-mated animals at 7 days of preg-
nancy, P-STAT5 was observed in ER-positive and alveo-
lar cells of both WT and Wip1 KO mice (Figure 3D, E).
This illustrates two points: (a) defective STAT5 activa-
tion in Wip1 KO hormone-sensing cells is rescued in
the presence of a pregnancy-associated hormonal milieu,
and (b) alveolar cells appear largely unaffected by the
absence of Wip1 in their response to pregnancy signals.
Hormone-receptor expression is unaffected in the
absence of Wip1
To determine whether the lack of STAT5 activation in
Wip1-deficient hormone-sensing cells is due to a reduc-
tion in prolactin-receptor expression, mammary epithe-
lial subsets were sorted for qPCR analysis. Basal and
luminal subsets were identified by using CD24 and
CD49f (a6-integrin; Figure 4A), after exclusion of debris,
doublets, dead cells, and lymphocytes, as outlined in
Additional file 2. This was followed by discrimination of
alveolar progenitor- and hormone sensing-enriched frac-
tions by using Sca1 (Ly6A) and CD49b (a2-integrin,
Figure 4B). Subpopulations were validated based on the
expression of alveolar (Elf5 and b-casein [34]) and hor-
mone-sensing cell markers (ER and PR) (Figure 4C) by
using a direct qPCR protocol developed for the conveni-
ent interrogation of gene expression in small numbers
of cells. For each population, two to three independent
tubes of 500 sorted cells were assayed per animal.
Analysis of Wip1 transcription in the cellular subsets
showed that Wip1 is expressed in all mammary epithe-
lial cells, with a higher level of transcription in alveolar
progenitor cells (Figure 4E). We were unable to achieve
a specific antibody staining for Wip1 protein in mouse
cells, based on Wip1 KO control sections (data not
shown), and could therefore not assess whether Wip1
protein levels reflect transcript levels. Even though Wip1
transcription is lower in hormone-sensing cells com-
pared with alveolar cells, our data demonstrate a clear
functional role for Wip1 in ER-positive cells (Figures 2
and 3). It is noteworthy that by FACS analysis, the pro-
portion of hormone-sensing cells was not significantly
different between WT and Wip1 KO mice (Figure 4D),
and ER transcription was similar in WT and Wip1 KO
cells (Figure 4F). This suggests that the lower proportion
of ER-positive cells in Wip1 KO glands, when quantified
by confocal immunofluorescence (Figure 3C), likely
results from reduced ER protein expression/stability
rather than a loss of ER-positive cells. Despite this
potential reduction in ER protein, the activity of the
estrogen receptor did not seem to be affected in the
absence of Wip1, because PR transcription is dependent
on estrogen [35] and PR transcription was not reduced
in Wip1 KO samples (Figure 4G). Importantly, tran-
scription of the prolactin receptor was also not reduced
in Wip1-deficient cells (Figure 4H), indicating that the
lack of P-STAT5 is not due to a defect in receptor
expression. Together, these data highlight that receptors
for steroid sex hormones and prolactin are predomi-
nantly expressed in specialized hormone-sensing cells,
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Figure 3 Steroid-receptor-positive cells require Wip1 to respond to low levels of prolactin. (A, B) Confocal immunofluorescence of
mammary gland sections from virgin wild-type (WT, A) and Wip1-knockout (KO, B) mice detecting estrogen receptor-a (ER, green), phospho-
STAT5 (P-STAT5, red), and cytokeratin-8 (CK8, blue). Right panels, enlarged sections of images shown in A and B. (C) Percentage of ER+ luminal
cells in virgin WT (blue bar) and Wip1 KO mice (green bar). Values represent the mean proportions from six mice/group ± SD. *P < 0.05. (D, E)
Confocal immunofluorescence of 7-day pregnant WT (D) and Wip1 KO (E) mammary sections detecting estrogen receptor-a (ER, green), P-STAT5
(P-STAT5, red), and cytokeratin-8 (CK8, blue). Inset is enlarged section of the same image. Arrows, ER-positive cells; arrowheads, alveolar cells.
Images are representative of five animals. Scale bar, 10 μm.
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Figure 4 Hormone-receptor expression is unaffected in the absence of Wip1. (A, B) Flow-cytometric analysis of mammary epithelial cells
isolated from virgin wild-type (WT, blue) and Wip1-knockout mice (KO, green) and gated to remove dead cells/debris, doublets, and
lymphocytes (see gating strategy in Additional file 2). Luminal cells were separated into hormone-sensing (HS, red) and alveolar (Alv, purple)
subsets based on the expression of Sca1 and CD49b (B). (C) Subset identity was validated with qPCR for alveolar cells (E74-like factor 5 (Elf5) and
b-casein) and hormone-sensing cells (estrogen and progesterone receptor (ER and PR). (D) Proportion of hormone-sensing cells (Sca1hiCD49blo)
in WT (blue bars) and Wip1 KO mammary glands (green bars). Values are presented as the mean proportions from five mice/group ± SD.
(E) Relative Wip1 mRNA proportions in individual subsets of mammary epithelial cells. (F through H) Relative proportions of mRNA for estrogen
receptor (ERa, F), progesterone receptor (PR, G), and prolactin receptor (PrlR, H) in WT (blue bars) and Wip1 KO (green bars) epithelial subsets.
All qPCR data (E through H) are presented as the mean ± SD for three to four individual sets of WT and Wip1 KO animals.
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and their expression is not reduced in the absence of
Wip1.
Hormone-sensing cells produce less paracrine factors in
the absence of Wip1
Our observation that Wip1 allows hormone-sensing cells
but not alveolar progenitor cells to respond to low pro-
lactin levels raises the question: why is pregnancy-
induced alveolar development delayed in Wip1 KO mice?
To answer this question, we measured whether lack of
Wip1 affected the production of paracrine factors by
hormone-sensing cells, such as RANKL and IGF2. Mice
deficient for either RANKL or IGF2 have defects in
alveolar development in response to pregnancy [36-38].
RANKL is induced by progesterone and not by prolactin
[38], but is absent in Stat5-knockout animals [39], sug-
gesting that optimal RANKL transcription requires both
progesterone and prolactin signaling [40,41]. Accord-
ingly, we detected RANKL transcription predominantly
in hormone-sensing cells (Figure 5A, B). In the absence
of Wip1, a clear reduction in RANKL transcription






















































































































Figure 5 Hormone-sensing cells produce less paracrine factors in the absence of Wip1. Quantitative polymerase chain reaction (qPCR)
analysis of receptor activator of nuclear factor kappa-B ligand (RANKL; A, B), insulin-like growth factor-2 (IGF-2; C, D), and b-casein (E, F)
transcription in wild-type (WT, blue bars) and Wip1-knockout (KO, green bars) luminal subsets (hormone-sensing (HS, red) and alveolar cells (Alv,
purple)) obtained from virgin or 7-day pregnant mice. Data are presented as mean ± SD of three to four separate sets of WT and Wip1 KO
animals in three separate qPCR experiments. **P < 0.01, and *P < 0.05; n.d., not detectable.
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present but less pronounced in samples from 7-day preg-
nant animals (Figure 5A, B). IGF2 transcription was
undetectable in virgin samples, but increased dramati-
cally with pregnancy. It has been reported that IGF2 tran-
scription is induced by prolactin [38,42], and our analysis
of sorted cellular subsets from WT mammary glands
demonstrated that IGF2 is produced specifically in hor-
mone-sensing cells (Figure 5D). In Wip1-knockout sam-
ples, IGF2 transcription was significantly reduced at
7 days of pregnancy (Figure 5D), suggesting that even
during pregnancy, prolactin signaling in hormone-
sensing cells may not be fully active without Wip1.
Notably, transcription of the milk gene b-casein in an
equal number of sorted alveolar cells is not reduced in
the absence of Wip1 (Figure 5E, F), suggesting that pro-
lactin signaling in alveolar cells, as detected by P-STAT5
at 7 days of pregnancy (Figure 3E), is Wip1 independent.
Overall, these findings show that hormone-sensing cells
produce not only RANKL but also IGF2, and limited
expression of these paracrine factors in the Wip1 KO
provides a likely explanation for the reduced alveolar
development in the initial stages of pregnancy.
Hormone-sensing cells are dependent on Wip1 for their
response to HER2/neu activation
Thus far we have identified a surprising role for Wip1 in
the function of hormone-sensing cells rather than of
alveolar progenitor cells, and this prompted us to investi-
gate how these different cell types respond to HER2/neu
activation in the presence or absence of Wip1. To this
end, MMTV-neu mice were crossed with Wip1 KO mice,
and mammary glands from MMTV-neu;Wip1 WT and
MMTV-neu;Wip1 KO mice were fixed, sectioned, and
immunostained for phosphorylated ERK (P-ERK) and
P-STAT5. Interestingly, phosphorylation of ERK by
HER2/neu activation was more pronounced in hormone-
sensing cells compared with alveolar progenitor cells
(Figure 6A). In the absence of Wip1, ERK activation by
HER2/neu in hormone-sensing cells was significantly
reduced (Figure 6B, quantified in 6C).
In mammary glands expressing Wip1, P-STAT5 was
detectable in hormone-sensing cells, as before (Figures 3A,
6D and 6G). We did not detect P-STAT5 in alveolar pro-
genitor cells in virgin mammary glands (Figure 3A), but
strikingly, in the presence of activated HER2/neu, STAT5
was phosphorylated in alveolar progenitor cells as well
(Figure 6D). Likewise, in mammary glands from virgin
Wip1-knockout animals, alveolar progenitor cells are posi-
tive for P-STAT5 in the presence of activated HER2/neu
(Figure 6E), demonstrating that this effect is Wip1 inde-
pendent. In contrast, the proportion of P-STAT5-positive
hormone-sensing cells was still significantly reduced in the
absence of Wip1 (Figure 6E). Thus, the defect in STAT5
activation in Wip1 KO hormone-sensing cells persists in
the presence of activated HER2/neu, but both wild-type
and Wip1 KO alveolar progenitor cells respond to HER2/
neu by activating STAT5 (Figure 6F). These findings
demonstrate that HER2/neu signaling is active in Wip1-
deficient alveolar progenitor cells, the presumptive cells of
origin for MMTV-neu tumorigenesis. In contrast, hor-
mone-sensing cells require Wip1 to respond to HER2/neu
activation with either ERK or STAT5 activation (Figure
6G), highlighting the importance of cell context in signal
transduction. qPCR data on cell subsets sorted from
MMTV-neu mammary glands demonstrated that RANKL
transcription in hormone-sensing cells remains low in
the absence of Wip1, even when HER2/neu is activated
(Figure 6H), consistent with the lack of STAT5 activation
in these cells. Interestingly, hormone-sensing cells are
intermingled with ER-negative cells in intraductal lesions
of MMTV-neu mammary glands (see Additional file 6),
raising the possibility that paracrine stimulation and Wip1
activity continue to play a role at this later stage of
tumorigenesis.
Discussion
Wip1 potentiates the response of hormone-sensing cells
to prolactin
In adult mammary glands of virgin mice, we found that
Wip1 is required for STAT5 activation, specifically in
hormone-sensing cells. Because of the obvious require-
ment for prolactin signaling and STAT5 activation in
alveolar development and milk production, the role of
STAT5 in alveolar cells has received the most attention
[19,43]. We showed for the first time that phosphorylated
STAT5 colocalizes only with ER- and PR-positive cells in
mammary epithelium of nonmanipulated virgin animals.
Because phosphorylation of STAT5 in virgin mammary
epithelium is strictly dependent on the presence of the
prolactin receptor [32], our data demonstrate that hor-
mone-sensing cells are the principal responders to pro-
lactin in the virgin state. This is consistent with previous
studies that described a similar pattern for progesterone-
receptor and prolactin-receptor expression in virgin
mammary glands [44,45]. Moreover, a study with ovar-
iectomized mice showed that soon after estrogen and
progesterone injection, STAT5 was localized to the
nucleus of steroid-receptor-positive cells specifically, with
translocation to the cytoplasm on inhibition of pituitary
prolactin secretion [46], again illustrating the capacity of
hormone-sensing cells to respond to prolactin.
During pregnancy, when prolactin levels increase sub-
stantially [33], we observed phosphorylated STAT5 not
only in the hormone-sensing cells, but also in alveolar
cells. Others have shown that injection of supraphysiologic
levels of prolactin caused STAT5 activation in all luminal
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cells, in contrast to the scattered pattern observed in the
nonmanipulated state [17,32]. This strongly suggests that
the higher levels of prolactin during pregnancy activate
STAT5 in alveolar cells, rather than alternative pregnancy-
induced signaling pathways. Altogether, these findings indi-
cate that although alveolar cells are capable of responding
directly to prolactin, their threshold for STAT5 activation
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Figure 6 Hormone-sensing cells are dependent on Wip1 for their response to Her2/neu activation. (A, B) Confocal immunofluorescence
detecting phosphorylated extracellular signal-regulated kinase (P-ERK, red), estrogen receptor-a (ER, green), and cytokeratin-8 (blue) in MMTV
(mouse mammary tumor virus)-neu Wip1 wild-type (WT; MMTV-neu, A) or MMTV-neu Wip1-knockout (KO; MMTV-neu, B) mammary epithelium.
(C) Quantification of the proportion of ER-positive (ER+) luminal cells positive for phospho-ERK. Values are presented as the mean proportions
from three to five mice/group ± SD. **P < 0.001. (D, E) Confocal immunofluorescence detecting phosphorylated signal transducer and activator
of transcription 5 (P-STAT5, red), estrogen receptor-a (ER, green), and cytokeratin-8 (CK8, blue) in MMTV-neu Wip1 wild-type (WT; MMTV-neu, D)
or MMTV-neu Wip1 KO (KO; MMTV-neu, E) mammary epithelium. Scale bar, 10 μm. Arrows, ER-positive cells; arrowheads, alveolar cells.
(F) Quantification of the proportion of ER-positive or ER-negative luminal cells positive for phospho-STAT5. Values are presented as the mean
proportions from five mice/group ± SD. ***P < 0.01. (G) Summary of immunostaining intensities for phospho-STAT5 and phospho-ERK in
Neu-positive wild-type and Wip1 KO virgin and pregnant mice, and in the context of MMTV-neu. (H) Receptor activator of nuclear factor kappa-B
ligand (RANKL) transcription in Neu-positive wild-type (blue bars) and Wip1 KO (green bars) luminal subsets (hormone sensing (HS, red) and
alveolar cells (purple)). Data are presented as mean ± SD of two separate sets of wild-type and Wip1 KO animals.
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Strikingly, the ability of hormone-sensing cells to
respond to low levels of prolactin is strictly dependent
on Wip1 expression, as indicated by virtually undetect-
able levels of activated STAT5 in Wip1-knockout mam-
mary epithelium. STAT5 activation in Wip1-deficient
hormone-sensing cells is rescued by day 7 of pregnancy,
suggesting that hormone-sensing cells are able to acti-
vate STAT5 in the absence of Wip1 when prolactin
levels are high enough, but require Wip1 to potentiate
the signal transduction in the virgin state. Even though
Wip1 is expressed in alveolar progenitor cells, activated
STAT5 is not detectable in the virgin state, which
implies that the target for Wip1 that allows potentiation
of prolactin signaling is either not present or not avail-
able in alveolar progenitor cells. It is currently unclear
what the relevant target is for Wip1 in hormone-sensing
cells that allows STAT5 activation. Several targets for
Wip1 have been identified, including various proteins
involved in DNA-damage signaling, as well as the stress
kinase p38MAPK [6]. Although we cannot rule out at
this stage that prolonged DNA-damage signaling and
p53 activation prevent STAT5 activation, hyperactiva-
tion of p38MAPK in the absence of Wip1 seems a more
likely cause of the lack of P-STAT5, based on the obser-
vation that p38MAPK inhibits JAK-STAT signaling in
monocytes [47] and because treatment of MMTV-neu;
Wip1 KO animals with a p38MAPK inhibitor restored
tumorigenesis, at least partially [4]. Unfortunately, the
increased sensitivity of hormone-sensing cells to prolac-
tin is lost when primary mammary epithelial cells are
taken into culture (data not shown), further emphasizing
the importance of cell and tissue context for the role of
Wip1 in mammary tumorigenesis and highlighting the
need for more sophisticated mouse models to dissect
the molecular mechanism.
Different role for prolactin signaling in hormone-sensing
versus alveolar cells
Our data show that cell context is also important for the
downstream effect of prolactin-receptor activation. For
instance, STAT5 activation results in milk-gene transcrip-
tion only in alveolar cells and not in hormone-sensing
cells. Experiments in cell lines suggest that both ER and
PR can prevent binding of STAT5 to the b-casein promo-
ter [48,49], illustrating how the molecular circuitry of a
particular cell type can direct the transcriptional response
to, for example, prolactin signaling. Similarly, we showed
that IGF2 transcription occurs in hormone-sensing cells
but not alveolar cells when both cells are responding to
prolactin (at 7 days of pregnancy). Whether IGF2 is a
direct target for STAT5 in hormone-sensing cells [38,50]
and how its transcription is prevented in alveolar cells
remains to be established. Interestingly, the IGF2-knock-
out mouse phenocopies the defect in alveologenesis
observed in the Wip1-knockout mouse. In both cases, a
considerable delay in alveolar development occurs during
the first half of pregnancy, and this is rescued late in preg-
nancy, and IGF2 KO as well as Wip1 KO animals are cap-
able of nursing their pups ([38] and DB/AP unpublished
observation). Ectopic IGF2 expression rescues alveolar
morphogenesis but not milk-gene transcription in prolac-
tin-receptor knockout mammary epithelium [38].
Together with our data, this suggests that the initial phase
of alveologenesis is dependent on prolactin signaling
relayed by hormone-sensing cells, whereas prolactin sig-
naling in alveolar cells themselves is required during the
later stages of pregnancy to initiate milk production.
Hormone-sensing cells also transcribe less RANKL in
the absence of Wip1. It has been shown that RANKL
expression is dependent on progesterone [51]; however,
it is currently unknown whether PR activity is reduced
in Wip1 KO mice. In luciferase promoter assays using
cancer cells, Wip1 was shown to enhance both ER and
PR activity [52], but we do not observe a decrease in PR
transcription, suggesting that ER activity is not affected
by Wip1 loss. Considering that RANKL expression is
substantially reduced in Stat5-knockout mice [39], we
interpret the lack of IGF2 and RANKL expression by
Wip1 KO hormone-sensing cells to be due to reduced
prolactin signaling. Both paracrine factors have been
shown to be important for promoting alveolar develop-
ment [38,53], providing an explanation for the reduced
alveologenesis in Wip1-knockout animals.
The role of hormone-sensing cells in early tumorigenesis
We found a defect in STAT5 activation in Wip1-deficient
hormone-sensing cells, even in the presence of activated
HER2/neu. Several studies demonstrate that interfering
with hormone-sensing cell function delays mammary
tumorigenesis. For instance, tamoxifen treatment of young
MMTV-neu mice results in a delay in tumor formation
that is uncannily similar to the one observed in the
absence of Wip1 [4,54]. Interestingly, tamoxifen not only
inhibits estrogen signaling, but it also reduces serum pro-
lactin levels [55] and prevents prolactin binding to its
receptor [56], raising the possibility that a reduction in
STAT5 activity was responsible for reduced tumor forma-
tion in this setting. Notably, once the (ER-negative)
tumors had developed, tamoxifen treatment did not inhi-
bit their growth [54], highlighting the specific requirement
for functional hormone-sensing cells during premalignant
development. Tamoxifen treatment also delayed tumori-
genesis in other mouse models of estrogen-receptor-nega-
tive mammary tumors [55], and the lack of prolactin-
receptor expression reduced proliferation in early lesions
and delayed SV40-driven tumorigenesis, but did not affect
growth of the tumors once they occurred [57]. Similarly,
deletion of Jak2 from mammary epithelial cells in general
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protected against tumor development in the MMTV-neu
model, but deletion of Jak2 from tumor cells did not affect
their proliferation [58]. Finally, pharmacologic inhibition
of RANKL strongly reduced the number of premalignant
lesions in MMTV-neu mice [59]. Thus, the absence of
active STAT5 in Wip1 KO hormone-sensing cells and the
subsequent paucity of RANKL may be sufficient to explain
a delay in tumorigenesis.
Although alveolar progenitors are thought to be the
cells of origin for tumors in the MMTV-neu model, we
showed for the first time that HER2/neu activation trig-
gers a response in hormone-sensing cells, as indicated
by ERK activation, and this response is severely attenu-
ated in the absence of Wip1. Clearly, the MMTV-neu
model is different from sporadic tumorigenesis in that
the MMTV LTR drives activated HER2/neu expression
in multiple cell types simultaneously, including both
hormone-sensing and alveolar progenitor cells [28,60].
In a different mouse model, activated HER2/neu is
expressed by the endogenous promoter; mimicking
human HER2+ breast cancer more closely. Even though
the tumors that arise in this model also express milk
genes [61], it is presently unclear what the target cell is
















Figure 7 Model for the cell-type-specific role of Wip1 in the mammary gland. In the virgin state, Wip1 (also known as PPM1D; protein
phosphatase magnesium-dependent 1D) is required to sensitize hormone-sensing cells (HS, red) to prolactin by promoting phosphorylation of
signal transducer and activator of transcription 5 (STAT5), whereas STAT5 activation is undetectable in adjacent alveolar progenitor cells (Alv,
purple), even when Wip1 is expressed. During pregnancy, prolactin levels increase, and STAT5 is activated in both hormone-sensing and alveolar
progenitor cells (blue arrows), independent of Wip1. In the absence of Wip1, STAT5-induced transcription of b-casein in alveolar cells is
unaffected, but in hormone-sensing cells, transcription of paracrine regulators RANKL (receptor activator of nuclear factor kappa-B ligand) and
IGF2 (insulin-like growth factor-2) is significantly reduced. In the context of HER2/neu (human epidermal growth factor receptor 2) activation,
STAT5 is phosphorylated in alveolar progenitor cells independent of Wip1, but Wip1 is required for both STAT5 and ERK (extracellular signal-
regulated kinase) activation in hormone-sensing cells. Thus, Wip1 potentiates prolactin and HER2/neu signaling specifically in hormone-sensing
cells and is important for the production of paracrine stimulators of alveolar development.
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least a subset of HER2+ breast cancers are ER+ [62],
raising the possibility that these tumors arise from
transformation of cells in the hormone-sensing lineage.
It will be important to find out whether human steroid-
receptor-positive cells also require Wip1 for their
response to prolactin and HER2/neu activation. This is
particularly relevant because women with elevated
serum prolactin levels have an increased risk of breast
cancer [63]. Our findings highlight that prolactin signal-
ing in hormone-sensing cells contributes to the growth-
promoting rather than to the differentiation-inducing
effects of prolactin. It seems that alveolar progenitor
cells are especially dependent on this paracrine stimula-
tion in early pregnancy and at the early stages of tumor-
igenesis. Thus, inhibiting the function of hormone-
sensing cells might reduce the occurrence not only of
ER+ breast cancer, but could also hamper premalignant
development of ER- breast cancer [54,64,65]. Currently,
Wip1 inhibitors are under development [66], prompted
by the observation that cells from established tumors
with Wip1 amplification remain dependent on Wip1 for
their survival [67]. Although our study does not address
the effect of Wip1 over-expression in tumor cells, our
data do suggest that it would be worthwhile to explore
the use of Wip1 inhibitors for preventive treatment,
similar to the recently approved use of tamoxifen in
women with a high risk of breast cancer [55,68]. Also,
the addition of Wip1 inhibitors as adjuvant therapy to
standard chemotherapeutic regimens may be of use in
extending recurrence-free survival.
Overall, our study underscores the relevance of cell con-
text in signal transduction and highlights the role of hor-
mone-sensing cells as integrators of systemic signals and
their subsequent influence on normal and premalignant
development.
Conclusions
We showed that distinct mammary epithelial cell types
respond differently to prolactin signaling (Figure 7). Spe-
cifically, hormone-receptor-positive cells already activate
STAT5 in the virgin state and transcribe the paracrine
factors RANKL and IGF2. In contrast, alveolar progenitor
cells detect prolactin only during pregnancy where and
STAT5 activation results in milk-gene transcription. The
Wip1 phosphatase potentiates prolactin signaling and is
required for ERK activation by HER2/neu in hormone-
sensing cells but not in alveolar progenitor cells. There-
fore, the delay in MMTV-neu tumorigenesis in the
absence of Wip1 is likely due to a lack of paracrine sti-
mulation of alveolar progenitor cells. Overall, our find-
ings underscore the relevance of cell context in signal
transduction and suggest a novel strategy to prevent
breast cancer progression: indirectly, by inhibiting the
hormone-sensing cells in their role as central conductors
of proliferation.
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